Nathan Pennell, Senior Vice President, Global Medical Oncology at Bristol Myers Squibb, shared on LinkedIn:
“Years in the clinic have taught me to ask three questions about every new treatment:
- How well does it work?
- What does the safety profile look like?
- How can we work to make sure it reaches the patients who need it?
The Phase 3 EXCALIBER-RRMM results presented at IMS26 today give me real reason for optimism on all three counts. I’m genuinely excited by what they could mean for patients with relapsed/refractory multiple myeloma.
Having spent years working toward a future where more patients actually receive the medicines they need, I couldn’t be prouder to be part of a team accelerating the journey from scientific discovery to patient impact. Thank you to the colleagues, investigators and patients advancing this critical research.”
